Last reviewed · How we verify
Gardasil® HPV vaccine
Gardasil® HPV vaccine is a Biologic drug developed by London School of Hygiene and Tropical Medicine. It is currently FDA-approved. Also known as: 4-valent HPV vaccine.
At a glance
| Generic name | Gardasil® HPV vaccine |
|---|---|
| Also known as | 4-valent HPV vaccine |
| Sponsor | London School of Hygiene and Tropical Medicine |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia (PHASE4)
- Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076) (PHASE3)
- Efficacy of Lentinula Edodes-Derived Supplement (AHCC®) in Promoting Negativity of Persistent HPV Infection
- Efficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval* for Adults With Recurrent Respiratory Papillomatosis* (PHASE1, PHASE2)
- Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV. (PHASE4)
- Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents (PHASE3)
- Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania (PHASE4)
- HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gardasil® HPV vaccine CI brief — competitive landscape report
- Gardasil® HPV vaccine updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI
Frequently asked questions about Gardasil® HPV vaccine
What is Gardasil® HPV vaccine?
Gardasil® HPV vaccine is a Biologic drug developed by London School of Hygiene and Tropical Medicine.
Who makes Gardasil® HPV vaccine?
Gardasil® HPV vaccine is developed and marketed by London School of Hygiene and Tropical Medicine (see full London School of Hygiene and Tropical Medicine pipeline at /company/london-school-of-hygiene-and-tropical-medicine).
Is Gardasil® HPV vaccine also known as anything else?
Gardasil® HPV vaccine is also known as 4-valent HPV vaccine.
What development phase is Gardasil® HPV vaccine in?
Gardasil® HPV vaccine is FDA-approved (marketed).
Related
- Manufacturer: London School of Hygiene and Tropical Medicine — full pipeline
- Also known as: 4-valent HPV vaccine
- Compare: Gardasil® HPV vaccine vs similar drugs
- Pricing: Gardasil® HPV vaccine cost, discount & access